In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insulet Corp.

https://www.insulet.com

Latest From Insulet Corp.

Market Intel: Managing Diabetes With Digital Apps: Physicians' Views On Pros And Cons

With a growing number of diabetes apps on the market, patients and physicians can obtain a large amount of data to help manage the disease. In this second part of a two-part series on the blood glucose monitoring devices market, two endocrinologists express their views on the considerations and pitfalls of using apps to help manage diabetes, and they recommend specific apps.

Diabetic Care Digital Health

ADA2018: Insulet Reports Positive Clinical Results For Omnipod Horizon, Limited Market Release Of Dash

Insulet Corp. plans a limited market release in the second half of this year of its recently FDA-cleared Omnipod Dash Insulin Management System through the pharmacy channel. Results from the most recent clinical trial supporting the Omnipod hybrid closed-loop system were presented this week's American Diabetes Association meeting in Orlando.

Diabetic Care Commercial

Market Intel: Insulin Pumps Dominate $7bn-Plus Global Infusion Devices Market

The global infusion drug delivery market continues to be driven by the rising prevalence of chronic disease and associated obesity, coupled with a growing aging population. Technological advancements such as less invasive pumps, needlestick prevention features and miniaturization have also supported the growing demand, but obstacles such as safety and security issues remain. According to a new report by Meddevicetracker, the global market for infusion pumps and disposables will reach $9.9bn by 2022, a CAGR of 6.4% from 2017. This article takes an in-depth look at the overall infusion pumps market, and dives deeper into the three fastest-growing segments – insulin, enteral and disposable pumps – highlighting the key players and competitive landscape.

Metabolic Market Intelligence

Insulet To Pay $19.5m Settlement In Investor Fraud Case

Insulet has agreed to pay $19.5m to settle claims it misled investors about the safety and success of its Eros insulin infusion pump at launch.
Medical Device Legal Issues
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Glucose Testing
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
    • Monitoring Equipment & Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Insulet Corp.
  • Senior Management
  • Shacey Petrovic, Pres. & CEO
    Wayde McMillan, EVP, CFO
    Eric Benjamin, SVP, R&D
  • Contact Info
  • Insulet Corp.
    Phone: (978) 600-7000
    100 Nagog Park
    Acton, MA 01720
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register